Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Diffuse Large B-cell Lymphoma”

542 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 542 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05253118
What this trial is testing

Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

Who this might be right for
DLBCL
Seoul National University Hospital 28
Early research (Phase 1)Enrolling By InvitationNCT06827782
What this trial is testing

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

Who this might be right for
Refractory/Recurrent Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University 42
Testing effectiveness (Phase 2)Study completedNCT00448201
What this trial is testing

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
UNC Lineberger Comprehensive Cancer Center 71
Testing effectiveness (Phase 2)Temporarily pausedNCT06761677
What this trial is testing

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

Who this might be right for
Relapsed or Refractory Lymphoma Including ENKL
SymBio Pharmaceuticals 43
Early research (Phase 1)Study completedNCT02992483
What this trial is testing

Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Novartis Pharmaceuticals 31
Not applicableEnded earlyNCT00813501
What this trial is testing

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseInfection+7 more
City of Hope Medical Center 60
Early research (Phase 1)Active Not RecruitingNCT04007029
What this trial is testing

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
CD19 PositiveCD20 PositiveRecurrent Chronic Lymphocytic Leukemia+11 more
Jonsson Comprehensive Cancer Center 24
Testing effectiveness (Phase 2)WithdrawnNCT00776802
What this trial is testing

GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
La Jolla Pharmaceutical Company
Testing effectiveness (Phase 2)Study completedNCT00077194
What this trial is testing

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT00042666
What this trial is testing

Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

Who this might be right for
Non-Hodgkin's Lymphoma
Eli Lilly and Company 55
Testing effectiveness (Phase 2)UnknownNCT02851589
What this trial is testing

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Ended earlyNCT01799889
What this trial is testing

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaMantle Cell LymphomaDiffuse Large B-cell Lymphoma+2 more
Gilead Sciences 326
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06062641
What this trial is testing

Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

Who this might be right for
Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital 50
Large-scale testing (Phase 3)Ended earlyNCT04236141
What this trial is testing

Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Who this might be right for
Diffuse, Large B-Cell, Lymphoma
Hoffmann-La Roche 42
Testing effectiveness (Phase 2)Ended earlyNCT05179603
What this trial is testing

SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Who this might be right for
Classic Hodgkin LymphomaDiffuse Large B-cell Lymphoma
Sanofi 14
Testing effectiveness (Phase 2)Ended earlyNCT02594163
What this trial is testing

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma RefractoryFollicular B-cell Non-Hodgkin's Lymphoma
Seagen Inc. 25
Early research (Phase 1)Study completedNCT03527147
What this trial is testing

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

Who this might be right for
NHLDLBCLNon-hodgkin's Lymphoma+1 more
Acerta Pharma BV 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03038672
What this trial is testing

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Who this might be right for
ALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+32 more
National Cancer Institute (NCI) 54
Early research (Phase 1)Active Not RecruitingNCT03321643
What this trial is testing

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell Lymphoma+3 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT02142049
What this trial is testing

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma RelapsedDiffuse Large B Cell Lymphoma Refractory
Pharmacyclics LLC. 35
Load More Results
24